[go: up one dir, main page]

MX2018015872A - Derivados de benzodioxano y su uso farmaceutico. - Google Patents

Derivados de benzodioxano y su uso farmaceutico.

Info

Publication number
MX2018015872A
MX2018015872A MX2018015872A MX2018015872A MX2018015872A MX 2018015872 A MX2018015872 A MX 2018015872A MX 2018015872 A MX2018015872 A MX 2018015872A MX 2018015872 A MX2018015872 A MX 2018015872A MX 2018015872 A MX2018015872 A MX 2018015872A
Authority
MX
Mexico
Prior art keywords
pharmaceutical use
benzodioxane derivatives
benzodioxane
derivatives
alpha2c
Prior art date
Application number
MX2018015872A
Other languages
English (en)
Inventor
Pohjakallio Antti
Pystynen Jarmo
Haikarainen Anssi
Kumpulainen Esa
Wang Shouming
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2018015872A publication Critical patent/MX2018015872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos de la fórmula I, (ver Fórmula) en donde Ra y Rb son como se define en las reivindicaciones, exhiben actividad antagonistica alfa2C y son de este modo útiles como antagonistas alfa2C.
MX2018015872A 2016-06-29 2017-06-28 Derivados de benzodioxano y su uso farmaceutico. MX2018015872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20165536 2016-06-29
PCT/FI2017/050484 WO2018002437A1 (en) 2016-06-29 2017-06-28 Benzodioxane derivatives and their pharmaceutical use

Publications (1)

Publication Number Publication Date
MX2018015872A true MX2018015872A (es) 2019-04-22

Family

ID=59501477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015872A MX2018015872A (es) 2016-06-29 2017-06-28 Derivados de benzodioxano y su uso farmaceutico.

Country Status (12)

Country Link
US (1) US20190152992A1 (es)
EP (1) EP3478676A1 (es)
JP (1) JP2019519582A (es)
KR (1) KR20190020343A (es)
CN (1) CN109415355A (es)
AU (1) AU2017287919A1 (es)
CA (1) CA3029109A1 (es)
EA (1) EA201990158A1 (es)
IL (1) IL263969A (es)
MX (1) MX2018015872A (es)
WO (1) WO2018002437A1 (es)
ZA (1) ZA201808060B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543231A1 (en) * 2018-03-19 2019-09-25 ETH Zurich Compounds for treating cns- and neurodegenerative diseases
EP3810593A1 (en) * 2018-06-20 2021-04-28 Janssen Pharmaceutica NV Oga inhibitor compounds
US20210300900A1 (en) * 2018-06-20 2021-09-30 Janssen Pharmaceutica Nv Oga inhibitor compounds
US20210261527A1 (en) * 2018-06-20 2021-08-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
CN118765280A (zh) * 2022-02-28 2024-10-11 维泰瑞隆有限公司 Rip1调节剂、其制备及用途
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
JP2025535295A (ja) 2022-10-18 2025-10-24 ファイザー・インク パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622569A (en) 1969-08-05 1971-11-23 R & L Molecular Research Ltd 6-(2-aryl-3-azido-and-3-amino-methyl-isocrotonamido)penicillanic acids
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
AU674569B2 (en) 1993-02-16 1997-01-02 Ube Industries, Ltd. Quinoline derivative
US5703115A (en) * 1993-02-19 1997-12-30 Janssen Pharmaceutica, N.V. (benzodioxan, benzofuran or benzopyran) alkylamino! alkyl substituted guanidines
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9409944D0 (en) 1994-05-17 1994-07-06 Rhone Poulenc Agriculture New compositions of matter
JPH11180979A (ja) * 1997-10-17 1999-07-06 Hokuriku Seiyaku Co Ltd 環状アミン誘導体
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
FR2795727B1 (fr) * 1999-06-29 2001-09-21 Pf Medicament Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique
DE60316672T2 (de) 2002-04-03 2008-07-17 Orion Corp. Polycyclische verbindungen als potente alpha2-adrenoceptor antagonisten
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
GT200600159A (es) * 2005-04-22 2007-03-14 Derivados benzodioxano y benzodioxolano y usos de los mismos
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CL2007002261A1 (es) 2006-08-04 2008-05-02 Takeda Pharmaceutical Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
US20110281821A9 (en) 2007-01-30 2011-11-17 Biogen Idec Ma Inc. Modulators of Mitotic Kinases
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
WO2011085261A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
AR104882A1 (es) * 2015-06-05 2017-08-23 Orion Corp DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C

Also Published As

Publication number Publication date
KR20190020343A (ko) 2019-02-28
EA201990158A1 (ru) 2019-05-31
AU2017287919A1 (en) 2019-01-17
EP3478676A1 (en) 2019-05-08
JP2019519582A (ja) 2019-07-11
WO2018002437A1 (en) 2018-01-04
IL263969A (en) 2019-01-31
CA3029109A1 (en) 2018-01-04
CN109415355A (zh) 2019-03-01
ZA201808060B (en) 2019-08-28
US20190152992A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
PH12020550703A1 (en) Sulfonamide compounds and use thereof
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MD3313851T2 (ro) Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
GEP20186910B (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MY185491A (en) Macrocylic pyrimidine derivatives
UA118120C2 (uk) Макроциклічні похідні піридину
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
JOP20190163A1 (ar) منشط nrf2
EA201691741A1 (ru) Фармацевтическая композиция
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.